Selective Signaling Control

Interrupt the damage. Preserve the maintenance.

Read the project brief Explore evidence

Concept illustration / not experimental evidence

The program question

Can a harmful interaction be altered without sacrificing normal lysosomal maintenance or protective growth controls?

Investigate whether an unwanted signaling function can be separated from a protein’s essential cellular work. GNPTAB–STING is a documented external lead, not a Karam-owned or validated target.

[C01] [C06] [C12]

01 / WORKSTREAM

Map the functions separately

Distinguish the reported noncanonical signaling interaction from the protein’s maintenance roles; preserve cell-type and perturbation context.

02 / WORKSTREAM

Define independent confirmation

A proposed follow-up should test specialized function, cell identity and alternative explanations rather than relying on one attractive senescence marker.

03 / WORKSTREAM

Consider more than editing

A credible target might ultimately support a drug, RNA, protein or other modality. CRISPR can be a discovery method without being the eventual medicine.

What would justify the next step?

A selective effect must be reproduced and explained before a development asset is claimed. Rights, safety and target-specific delivery remain separate workstreams.

From question to decision

A program names the scientific direction. A project brief defines a proposed bounded work package. A commercial scope specifies what a buyer would receive and what must be qualified before contracting. These are related, but they are not interchangeable.

Research context

External work. Explicit limits.

2026-07-27 · China

Human cell models · Cas9 screen

GNPTAB–STING: separate harmful signaling from maintenance

A focused Cas9 screen identified GNPTAB as a regulator of senescence. The assessment describes a noncanonical interaction with STING and a binding-deficient mutant that retained the tested lysosomal functions without inducing senescence.

Target / subject: GNPTAB / STING
Direction: Disruption; overexpression; interaction separation
Cell / setting: Human mesenchymal progenitor cells
Boundary: This is mechanistic human-cell evidence, not treatment of people. Deleting or suppressing GNPTAB everywhere would not follow from an interaction-specific result.

2026-08-26 · Not assigned

Cells + animals · Cas9 outcome profiling

Off-target findings differ across cells and organs

Single-cell and in vivo profiling found heterogeneous off-target and translocation outcomes, including events obscured by bulk analysis. Some experiments deliberately used a promiscuous guide.

Target / subject: Guide- and tissue-specific loci
Direction: Off-target / translocation measurement
Cell / setting: Individual cells and mouse tissues
Boundary: The work does not provide a universal error rate for every editor or clinical guide. Results depend on the guide, cell population, delivery and assay sensitivity.

2026-03-28 · China

Cellular experiment · CRISPRa

POLR2A activation: cellular findings are not a checkpoint bypass license

Activating endogenous POLR2A with CRISPRa alleviated senescent phenotypes in the reported system. The assessment describes a pathway connecting LMO7-mediated regulation with MDM4, p53 and p21.

Target / subject: LMO7 / POLR2A / MDM4-p53-p21
Direction: Activation
Cell / setting: Senescence-associated cellular model
Boundary: This does not show that broad suppression of protective p53 signaling is a healthy-aging strategy. Specific context, identity and growth safeguards must remain visible.

Source trail

Scientific summaries are adapted from the supplied 15 October 2026 CRISPR Project Assessment. Source records show the original references and review access; this release is not a new systematic review.

C01 — Yin J, Gao Y, Jing Y, et al. CRISPR screening identifies GNPTAB as a noncanonical STING activator driving cellular senescence. Protein & Cell. 27 July 2026.C06 — Madsen A, Selfjord N, Martinez-Lage M, et al. Single-cell and in vivo profiling reveal heterogeneous and organ-specific CRISPR-Cas9 off-target and translocation outcomes. Nature Communications. 26 August 2026;17:9067.C12 — Lai C, Fu W, Liu J, et al. LMO7-mediated POLR2A degradation promotes cellular senescence through the MDM4/p53/p21 axis. Cell Death & Disease. 28 March 2026;17:421.

Bring one question worth answering.

Tell us the decision, the evidence you have and the gap that blocks the next step. Start with nonconfidential context.

Discuss a scope Explore the Atlas